Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-03-31
2010-02-02
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
Reexamination Certificate
active
07655459
ABSTRACT:
The present invention provides a pharmaceutical that safely and effectively enhances the anticancer activity of viral therapy and particularly the antitumor immunity of viral therapy. The present invention also provides a method of preventing or treating cancer that uses this drug. The anticancer activity enhancer according to the present invention contains interleukin as an effective component and is co-administered with a recombinant herpes simplex virus that selectively replicates in cancer cells.
REFERENCES:
patent: 2002/0187163 (2002-12-01), Johnson et al.
patent: 2003/0091537 (2003-05-01), Coffin
patent: 2001-513508 (2001-09-01), None
patent: WO 02/076216 (2002-10-01), None
Yamanaka et al, Cancer Immunol. Immunother. 1999, 48(6):297-302.
Hara et al, Cancer Gene Therapy, 2000, vol. 7, pp. 83-90.
Bennett et al, Annals of Surgery, 2001, vol. 233, No. 6, pp. 819-826.
Partial translation of: Seikagaku Jien (3rd Edition), Kabushiki Kaisha Tokyo Kagaku Dojin, 1998, p. 156, right column.
Martuza, et al.; Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant; May 10, 1991; Science, vol. 252; pp. 854-856.
Chahlavi, et al.; Replication—Competent Herpes Simplex Virus Vector G207 and Cisplatin Combination Therapy for Head and Neck Squamous Cell Carcinoma; Neoplasia, vol. 1, No. 2; Jun. 1999; pp. 162-169.
Hunter, et al.; Attenuated, Replication—Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates; Journal of Virology, vol. 73, No. 8, Aug. 1999; pp. 6319-6326.
Chahlavi, et al.; Effect of Prior Exposure to Herpes Simplex Virus 1 on Viral Vector—Medicated Tumor Therapy in Immunocompetent Mice; Gene Theraphy, vol. 6, 1999, pp. 1751-1758.
Nakamura, et al.; Glial Expression of Fibroblast Growth Factor-9 in Rat Central Nervous System; GLIA 28; 1999, pp. 53-65.
Todo, et al.; Systemic Antitumor Immunity in Experimental Brain Tumor Therapy Using a Multimutated, replication—Competent Herpes Simplex Virus; Human Gene Therapy, vol. 10; Nov. 20, 1999; pp. 2741-2755.
Todo, e al.; Corticosteroid Adminstration Does not Affect Viral Oncolytic Activity, but Inhibits Antihumor Immunty in Replication Competent Herpes Simplex Virus Tumor Therapy; Human Gene Theraphy vol. 10; Nov. 20, 1999; pp. 2869-2878.
Todo, et al.; Evaluation of Ganciclovir—Mediated Enhancement of the Antitumoral Effect in Oncolytic, Multimutated Herpes Simplex Virus Type 1(G207) Therapy of Brain Tumors; Cancer General Theraphy, vol. 7, No. 6, 2000; pp. 939-946.
Merkert, et al.; Conditionally replicating Herpes Simplex Virus Mutant, G207 for the treatment of malignant Glioma: results of phase 1 Trial; Gene Theraphy, vol. 7; 2000; pp. 867-874.
Toda, et al.; Viral Shedding and Biodistribution of G207, a Mulitmutated, Conditionally Replicating Herpes Simples Virus Type 1, After Intracerebral Inoculation in Aotus; Molecular Therapy, vol. 2, No. 6, pp. 588-595.
Nakano, et al.; Theraputic Efficacy of G207, a Conditionally Replicating herpes Simplex Virus Type 1 Mutant, for Gallbladder Carcinoma in Immunocompetent Hamsters; Molecular Therapy vol. 3, No. 4, Apr. 2001.
Varghese, et al., Preclinical Safety Evaluation of G207, a Replication Competent Herpes Simplex Virus Type 1, Inoculated Intraprostatically in Mice and Nonhuman Primates; Human Gene Therapy vol. 12; May 20, 2001; pp. 999-1010.
Jorgensen, et al.; Ionizing Radiation Does Not Alter the Antitumor Activity of Herpes Simplex Virus Vector G207 in Subcutaneous Tumor Models of Human and Murine Prostate Cancer; Neoplasia, vol. 3, No. 5; 2001; pp. 451-456.
Todo, et al.; Oncolytic Herpes Simplex Virus (G207) Therapy From Basic to Clinical; Tumor Supressing Viruses, Genes, and Drugs—Inovative Cancer Therapy Approaches; 2001; pp. 45-75.
Todo, et al.; Oncolytic Herpes Simplex Virus Vector With Enhanced MHC Class 1 presentation and Tumor Cel Killing; Pro. Natl. Acad. Sci. USA, 2001,vol. 92, pp. 6396-6401.
Todo, et al.; Herpes Simples Virus as an in Situ Cancer Vaccine for the Induction of Specific Anti-Tumor Immunity; Human Gene Therpy 10, Feb. 10, 1999; pp. 385-393.
Todo, et al.; In Situ Expression of Soluble B7-a in the Context of Oncolytic Herpes Simplex Virus Induces Potent Antitumor Immunity; Cancer Research, vol. 61; Jan. 1, 2001, pp. 153-161.
Katsanis, et al.; B7-1 Expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibilty complex and costimulatory molecules; Cancer Gene Therapy, vol. 2, No. 1, 1995; pp. 39-46.
Katsanis, et al.; Irradiation of Singly and Doubly Transduced Murine Neuroblastoma Cells Expressing B7-1 and Producing Interferon-Gamma Reduces their Capacity to induce Systemic Immunity; Cancer Gene Therapy, vol. 3, No. 2, 1996; pp. 75-82.
Heuer, et al.; Retrovirus-mediated Gene Transfer of B7-1 and MHC Class II Converts a Poorly Immunogenic Neuroblastoma into a Highly Immunogenic One; Human Gene Therapy, vol. 7, Nov. 10, 1996; pp. 2059-5068.
Seikagaku Jien (3rd Edition), Kabushiki Kaisha Tokyo Kagaku Dojin, 1998, p. 156, right column.
Varghese, et al.; Oncolytic Herpes Simplex Virus vectors for cancer Virotherapy; Cancer Gene Therapy, vol. 9, 2002; pp. 967-978.
Coughlin et al. Interleukin-12 and Interleukin-18 Synergistically Induce Murine Tumor Regression which Involves Inhibition of Angiogenesis. J. Clin. Invest: 101(6):144-1452 (1998).
Ino et al. Triple Combination of Oncolytic Herpes Simplex Virus-1 Vectors Armed with Interleukin-12, Interleukin-18, or soluble B7-1 results in Enhanced Antitumor Efficacy. Clin. Cancer Research 12:643-652 (2006).
Toda et al. In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity. J. Immunol. 160:4474-4464 (1998).
Morgan & Lewis & Bockius, LLP
Salimi Ali R.
LandOfFree
Enhancer of anticancer activity in viral therapy and method... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancer of anticancer activity in viral therapy and method..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancer of anticancer activity in viral therapy and method... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4213809